Terms: = Ovarian cancer AND PALB2, ENSG00000083093, 79728 AND Treatment
41 results:
1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
2. Targeting BRCA and palb2 in Pancreatic cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract] [Full Text] [Related]
3. [News in breast oncology genetics for female and male population].
Taris N; Luporsi E; Osada M; Thiblet M; Mathelin C
Gynecol Obstet Fertil Senol; 2024 Mar; 52(3):149-157. PubMed ID: 38190969
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast cancer.
Lynce F; Robson M
Cancer Treat Res; 2023; 186():91-102. PubMed ID: 37978132
[TBL] [Abstract] [Full Text] [Related]
5. Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond.
Rein HL; Bernstein KA
DNA Repair (Amst); 2023 Oct; 130():103563. PubMed ID: 37651978
[TBL] [Abstract] [Full Text] [Related]
6. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract] [Full Text] [Related]
7. The Clinical Implications of Reversions in Patients with Advanced Pancreatic cancer and Pathogenic Variants in BRCA1, BRCA2, or palb2 after Progression on Rucaparib.
Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA
Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343
[TBL] [Abstract] [Full Text] [Related]
8. The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
Li Y; Chen Z; Peng J; Yuan C; Yan S; Yang N; Li P; Kong B
Oncogene; 2023 Jul; 42(31):2386-2401. PubMed ID: 37391593
[TBL] [Abstract] [Full Text] [Related]
9. Prevalence of Pathogenic Germline Mutations in 13 Hereditary cancer-Related Genes in Breast cancer Patients in Narathiwat Province, Thailand.
Sukpan P; Kanokwiroon K; Sriplung H; Laochareonsuk W; Choochuen P; Auseng N; Wanawanakorn K; Sangkhathat S
Asian Pac J Cancer Prev; 2023 Feb; 24(2):525-530. PubMed ID: 36853301
[TBL] [Abstract] [Full Text] [Related]
10. The impact of coding germline variants on contralateral breast cancer risk and survival.
Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
[TBL] [Abstract] [Full Text] [Related]
11. Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan.
Masood A; Sarfaraz R; Zaki S; Shami A; Khaliq S; Naseem N
Cancer Biomark; 2023; 36(3):207-219. PubMed ID: 36776043
[TBL] [Abstract] [Full Text] [Related]
12. Moderate-Risk Genes for Hereditary ovarian cancers Involved in the Homologous Recombination Repair Pathway.
Abe A; Imoto I; Ueki A; Nomura H; Kanao H
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233090
[TBL] [Abstract] [Full Text] [Related]
13. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract] [Full Text] [Related]
14. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
15. Genetic testing for hereditary predisposition to breast cancer in the real world: Initial experience.
da Silva Fontinele DR; Assunção Ribeiro da Costa RE; da Silva Magalhães MK; Vieira SC
Breast Dis; 2022; 41(1):249-254. PubMed ID: 35570472
[TBL] [Abstract] [Full Text] [Related]
16. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and palb2 in a Tumor-Only Genomic Testing Program.
Bychkovsky BL; Li T; Sotelo J; Tayob N; Mercado J; Gomy I; Chittenden A; Kane S; Stokes S; Hughes ME; Kim JS; Umeton R; Awad MM; Konstantinopoulos PA; Yurgelun MB; Wolpin BM; Taplin ME; Newmark RE; Johnson BE; Lindeman NI; MacConaill LE; Garber JE; Lin NU
Clin Cancer Res; 2022 Jun; 28(11):2349-2360. PubMed ID: 35363308
[TBL] [Abstract] [Full Text] [Related]
17. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast cancers.
Huang CC; Tsai YF; Liu CY; Lien PJ; Lin YS; Chao TC; Feng CJ; Chen YJ; Lai JI; Phan NN; Hsu CY; Chiu JH; Tseng LM
Ann Surg Oncol; 2022 Jun; 29(6):3578-3590. PubMed ID: 35226219
[TBL] [Abstract] [Full Text] [Related]
18. Pancreatic cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract] [Full Text] [Related]
19. Germline palb2 Variants and PARP Inhibitors in Endometrial cancer.
Cilento MA; Poplawski NK; Paramasivam S; Thomas DM; Kichenadasse G
J Natl Compr Canc Netw; 2021 Nov; 19(11):1212-1217. PubMed ID: 34781271
[TBL] [Abstract] [Full Text] [Related]
20. Therapeutic Implications of Germline Testing in Patients With Advanced cancers.
Stadler ZK; Maio A; Chakravarty D; Kemel Y; Sheehan M; Salo-Mullen E; Tkachuk K; Fong CJ; Nguyen B; Erakky A; Cadoo K; Liu Y; Carlo MI; Latham A; Zhang H; Kundra R; Smith S; Galle J; Aghajanian C; Abu-Rustum N; Varghese A; O'Reilly EM; Morris M; Abida W; Walsh M; Drilon A; Jayakumaran G; Zehir A; Ladanyi M; Ceyhan-Birsoy O; Solit DB; Schultz N; Berger MF; Mandelker D; Diaz LA; Offit K; Robson ME
J Clin Oncol; 2021 Aug; 39(24):2698-2709. PubMed ID: 34133209
[TBL] [Abstract] [Full Text] [Related]
[Next]
